{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:04:04Z","timestamp":1783602244928,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This post hoc subgroup analysis was conducted using pooled data from three US\u2010based clinical trials to compare efficacy and safety of rimegepant 75\u2009mg versus placebo in acute migraine in adults who are Black or African American.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Migraine, characterized by recurring moderate\u2010to\u2010severe unilateral head pain, affects approximately 13% of the population and in the United States affects Black or African American and White populations at similar rates. Despite this, there is stark underrepresentation of Black or African American patients in clinical trials. Rimegepant, an oral small molecule calcitonin gene\u2010related peptide receptor blocker or antagonist, is approved for acute migraine treatment in the United States; however, treatment has not previously been analyzed in Black or African American adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using pooled data from three US\u2010based, double\u2010blind, randomized, placebo\u2010controlled, multicenter clinical trials (ClinicalTrials.gov, NCT03235479; NCT03237845; NCT03461757), efficacy analyses were conducted on a modified intent\u2010to\u2010treat population including all participants who received study medication, had a migraine attack of moderate or severe pain intensity at the time of dosing, and provided \u22651 efficacy datapoint after receiving study treatment. Trials were conducted July 2017 to January 2018 (NCT03235479, NCT03237845) or February 2018 to October 2018 (NCT03461757). The coprimary efficacy endpoints of each trial were freedom from pain (score 0\u2009=\u2009none on a 4\u2010point pain scale) and freedom from most bothersome symptom (MBS) at 2\u2009h post dose. Safety was assessed through reported on\u2010treatment adverse events, defined as events occurring on or after treatment was received. Analyses were performed in the Black or African American population, in the White population, and in the overall pooled study population (including Black or African American, White, Asian, American Indian or Alaskan Native, Native Hawaiian or other Pacific Islander, and multiple races).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 3551 treated participants were in the pooled population; 696 (19.6%) were Black or African American; 2700 (76.0%) were White. In the Black or African American population, rimegepant showed improvements versus placebo in the two coprimary endpoints. For pain freedom 2\u2009h post dose, the stratified risk was 24.4% (88\/359) for rimegepant and 18.2% (59\/323) for placebo in Black or African American participants; risk difference was 6.2% (95% confidence interval [CI]: 0.1, 12.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.047). For MBS freedom 2\u2009h post dose, the stratified risk was 43.1% (155\/359) for rimegepant and 35.5% (115\/323) for placebo in Black or African American participants; risk difference was 7.6% (95% CI: 0.3, 14.9;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041). The risk difference was similar in White participants: 7.9% (95% CI: 5.2, 10.6;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for pain freedom 2\u2009h post dose and 9.9% (95% CI: 6.5, 13.4;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) for MBS freedom 2\u2009h post dose. Adverse event rates among Black or African American participants treated with rimegepant were 10.7% (39\/365) and 7.9% (26\/331) in participants receiving placebo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This pooled analysis showed rimegepant 75\u2009mg was effective and well tolerated for migraine treatment in Black or African American adult participants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.70034","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:44:23Z","timestamp":1770443063000},"page":"874-884","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo\u2010controlled clinical trials"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7708-5394","authenticated-orcid":false,"suffix":"IV","given":"Larry","family":"Charleston","sequence":"first","affiliation":[{"name":"Department of Neurology Charleston Health Neurology &amp; Head Pain Consultants  Pinckney Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Armand","sequence":"additional","affiliation":[{"name":"Department of Neurology Albert Einstein College of Medicine  Bronx New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-252X","authenticated-orcid":false,"given":"Teshamae S.","family":"Monteith","sequence":"additional","affiliation":[{"name":"Department of Neurology University of Miami  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8121-825X","authenticated-orcid":false,"given":"Hope L.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Neurology Headache Center of Hope  Cincinnati Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra C.","family":"Abbott","sequence":"additional","affiliation":[{"name":"Pfizer Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn C.","family":"Pixton","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[{"name":"Pfizer Inc  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12506"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00453.x"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13018"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.113"},{"issue":"10","key":"e_1_2_12_6_1","first-page":"1","article-title":"Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment","volume":"94","author":"Burroughs VJ","year":"2002","journal-title":"J Natl Med Assoc"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvac040"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1449833"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-823356-6.00018-4"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13930"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_12_13_1","unstructured":"SAS Institute Inc.SAS.https:\/\/www.sas.com\/en_us\/home.html. Accessed 24 September 2025."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14797"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01294-8"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0718-1"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2057152"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2018-104811"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10194-007-0360-4"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420970489"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2072"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.2335"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.1.52"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70034","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.70034","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.70034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T07:24:18Z","timestamp":1775114658000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.70034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/head.70034"],"URL":"https:\/\/doi.org\/10.1111\/head.70034","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"2024-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}